Download PDF
CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0044-1788075
Case Report

High-Dose Epidermal Radionuclide Therapy with 188Re (Rhenium) Resin in a Patient with Multiple Actinic Keratoses

Siroos Mirzaei 
1   Department of Nuclear Medicine with PET-Centre, Clinic Ottakring, Vienna, Austria
,
Rainer Kunstfeld
2   University Department for Dermatology, Medical University Vienna, Vienna, Austria
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Aim High-dose epidermal radionuclide therapy using a nonsealed 188Re (Rhenium) resin is an alternative treatment option for nonmelanoma skin cancer. In this case study, we present the possible use of this therapy in a patient with multiple actinic keratosis (AK), which is a precancer of the skin.

Methods A 55-year-old male was presented in our department with multiple AK, located on the cheek, temporal, and frontal area, with 1, 1, 2.1, and 2.5 cm2 surface.

Applied activity was 80, 80, 167, and 168 MBq 188Re with a target absorbed dose for each lesion 35 Gy at 1 mm. The treatment was well tolerated.

Results At 17 months’ follow-up, all treated area showed complete remission. There were no side effects, except mild focal hypopigmentation.

Conclusion This case demonstrates the high potential of epidermal radionuclide therapy with a nonsealed 188Re as a noninvasive, effective, and well-tolerated therapy option for patients with multiple AK, when surgery is difficult to perform or not recommended of other reasons.

Keywords

actinic keratosis - epidermal therapy - radionuclide therapy - Rhenium-188 - skin cancer


Publication History

Article published online:
04 July 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Eric M, Chen TM. Actinic Keratosis. StatPearls Publishing; August 17, 2023. Accessed December 11, 2023 at: https://www.ncbi.nlm.nih.gov/books/NBK557401/
    Google Scholar
  • 2 Howell JY, Ramsey ML. Squamous Cell Skin Cancer. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023
    Google Scholar
  • 3 Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol 2008; 33 (06) 745-749
    CrossrefPubMedGoogle Scholar
  • 4 Carrozzo AM, Sedda AF, Muscardin L, Donati P, Cipriani C. Dermo beta brachytherapy with 188-Re in squamous cell carcinoma of the penis: a new therapy. Eur J Dermatol 2013; 23 (02) 183-188
    CrossrefPubMedGoogle Scholar
  • 5 Castellucci P, Savoia F, Farina A. et al. High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results. Eur J Nucl Med Mol Imaging 2021; 48 (05) 1511-1521
    CrossrefPubMedGoogle Scholar
  • 6 Ouhib Z, Kasper M, Perez Calatayud J. et al. Aspects of dosimetry and clinical practice of skin brachytherapy: the American Brachytherapy Society working group report. Brachytherapy 2015; 14 (06) 840-858
    CrossrefPubMedGoogle Scholar